Musiek Erik S, Holtzman David M
Department of Neurology, Knight Alzheimer's Disease Research Center, and Hope Center for Neurological Disorders, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Nat Neurosci. 2015 Jun;18(6):800-6. doi: 10.1038/nn.4018.
The amyloid hypothesis, which has been the predominant framework for research in Alzheimer's disease (AD), has been the source of considerable controversy. The amyloid hypothesis postulates that amyloid-β peptide (Aβ) is the causative agent in AD. It is strongly supported by data from rare autosomal dominant forms of AD. However, the evidence that Aβ causes or contributes to age-associated sporadic AD is more complex and less clear, prompting criticism of the hypothesis. We provide an overview of the major arguments for and against the amyloid hypothesis. We conclude that Aβ likely is the key initiator of a complex pathogenic cascade that causes AD. However, we argue that Aβ acts primarily as a trigger of other downstream processes, particularly tau aggregation, which mediate neurodegeneration. Aβ appears to be necessary, but not sufficient, to cause AD. Its major pathogenic effects may occur very early in the disease process.
淀粉样蛋白假说一直是阿尔茨海默病(AD)研究的主要框架,但该假说也引发了诸多争议。淀粉样蛋白假说认为,β淀粉样肽(Aβ)是AD的致病因子。来自罕见常染色体显性遗传形式AD的数据为该假说提供了有力支持。然而,关于Aβ导致或促成与年龄相关的散发性AD的证据更为复杂且尚不明确,这引发了对该假说的批评。我们概述了支持和反对淀粉样蛋白假说的主要论点。我们得出结论,Aβ可能是导致AD的复杂致病级联反应的关键启动因素。然而,我们认为Aβ主要作为其他下游过程的触发因素,特别是tau蛋白聚集,后者介导神经退行性变。Aβ似乎是导致AD的必要但非充分条件。其主要致病作用可能在疾病过程的早期就已出现。